MARKET

CMRX

CMRX

Chimerix
NASDAQ
4.060
-0.150
-3.56%
After Hours: 4.000 -0.06 -1.48% 19:43 02/10 EST
OPEN
4.210
PREV CLOSE
4.210
HIGH
4.250
LOW
3.940
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
0.7500
MARKET CAP
365.14M
P/E (TTM)
-4.3413
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CMRX last week (0203-0207)?
Weekly Report · 1d ago
Chimerix’s Strategic Progress and Upcoming Catalysts: A Promising Outlook for 2025
TipRanks · 6d ago
Weekly Report: what happened at CMRX last week (0127-0131)?
Weekly Report · 02/03 10:36
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
NASDAQ · 01/31 15:43
"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News
Benzinga · 01/27 17:50
Weekly Report: what happened at CMRX last week (0120-0124)?
Weekly Report · 01/27 10:38
CHIMERIX REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/24 21:01
Weekly Report: what happened at CMRX last week (0113-0117)?
Weekly Report · 01/20 10:32
More
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.

Webull offers Chimerix Inc stock information, including NASDAQ: CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.